DCVax-L has demonstrated significant clinical benefits in glioblastoma treatment, with phase III trial data showing mOS of 19.3 months for ndGBM patients overall, 30.2 months for MGMT-methylated ndGBM patients, and 13.2 months for rGBM patients (53, 57). Here, MGMT is linked to glioblastoma.